Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Yamaguchi, Japan.
In Vivo. 2021 Nov-Dec;35(6):3297-3303. doi: 10.21873/invivo.12625.
BACKGROUND/AIM: Recent experimental studies have reported that leukotriene receptor antagonists (LTRAs) might protect against dementia. However, few clinical studies have examined this in humans. This study assessed whether the use of LTRAs can prevent the onset of dementia in humans.
A large population-based retrospective cohort study was conducted using a health insurance claims database in Japan, which included patients newly diagnosed with bronchial asthma between 2006 and 2015. Each of these patients that was LTRA user was matched with a randomly selected LTRA non-user according to age, sex, and bronchial asthma diagnostic year.
There were 10,471 patients in both the LTRA user and the LTRA non-user group. Using Cox proportional hazards models, a significant reduction in the risk of developing dementia was observed in the LTRA user group compared to the non-user group (adjusted hazard ratio=0.42, 95% confidence interval=0.20-0.87, p=0.019).
Our data suggest that the use of LTRAs may prevent the onset of dementia in asthmatic patients.
背景/目的：最近的实验研究报告称，白三烯受体拮抗剂（LTRAs）可能有助于预防痴呆。然而，很少有临床研究在人类中对此进行了检验。本研究评估了 LTRAs 的使用是否可以预防人类痴呆的发生。
使用日本医疗保险索赔数据库进行了一项大型基于人群的回顾性队列研究，其中包括 2006 年至 2015 年间新诊断为支气管哮喘的患者。每个 LTRA 用户都与随机选择的 LTRA 非用户按照年龄、性别和支气管哮喘诊断年份进行匹配。
在 LTRA 用户组和 LTRA 非用户组中，各有 10471 名患者。使用 Cox 比例风险模型，与非使用者相比，LTRA 使用者组发生痴呆的风险显著降低（调整后的风险比=0.42，95%置信区间=0.20-0.87，p=0.019）。
我们的数据表明，LTRAs 的使用可能预防哮喘患者痴呆的发生。
